Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 982

1.
2.

Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators.

Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313. Epub 2009 Mar 30.

3.

Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study.

Nadelmann J, Frishman WH, Ooi WL, Tepper D, Greenberg S, Guzik H, Lazar EJ, Heiman M, Aronson M.

Am J Cardiol. 1990 Sep 1;66(5):533-7.

PMID:
2392974
4.
5.

Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension.

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C.

J Am Coll Cardiol. 1998 Feb;31(2):383-90.

6.

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. doi: 10.1016/j.jelectrocard.2009.06.020. Epub 2009 Jul 24.

PMID:
19631946
7.

Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.

Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB.

Circulation. 1994 Oct;90(4):1786-93.

PMID:
7923663
8.

Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.

Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.

J Hypertens Suppl. 1996 Dec;14(5):S43-9.

PMID:
9120684
9.

Hypertension: cardiovascular implications in a cohort of old old.

Guzik HJ, Ooi WL, Frishman WH, Greenberg S, Aronson MK.

J Am Geriatr Soc. 1992 Apr;40(4):348-53.

PMID:
1556362
10.

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.

11.

Improved cardiovascular risk stratification by a simple ECG index in hypertension.

Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, Borgioni C, Bentivoglio M, Porcellati C, Ambrosio G.

Am J Hypertens. 2003 Aug;16(8):646-52.

PMID:
12878370
12.

Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients.

Verdecchia P, Sleight P, Avanzini F, de Simone G, Pede S, Perticone F, Schillaci G, Vanuzzo D, Angeli F, Reboldi GP, Maggioni AP.

Ital Heart J. 2003 Jul;4(7):479-83.

PMID:
14558300
13.

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations.

Circulation. 2003 Aug 12;108(6):684-90. Epub 2003 Jul 28.

14.

Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study.

Verdecchia P, Reboldi G, Angeli F, Avanzini F, de Simone G, Pede S, Perticone F, Schillaci G, Vanuzzo D, Maggioni AP; HEART Survey Study Group.

Am J Hypertens. 2007 Sep;20(9):997-1004.

PMID:
17765142
15.

Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.

Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, Thomopoulos C, Syrseloudis D, Stefanadi E, Mihas C, Katsi V, Papademetriou V, Stefanadis C.

J Hypertens. 2009 Apr;27(4):744-52. doi: 10.1097/HJH.0b013e32832401ff.

PMID:
19516174
16.

Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.

Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, Bosch J, Baird M, Dagenais G, Sleight P, Yusuf S; Heart Outcomes Prevention Evaluation Study Investigators.

Eur J Cardiovasc Prev Rehabil. 2003 Dec;10(6):420-8.

PMID:
14671464
17.
18.

Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction.

Yotsukura M, Suzuki J, Yamaguchi T, Sasaki K, Koide Y, Mizuno H, Yoshino H, Ishikawa K.

J Electrocardiol. 1998 Apr;31(2):91-9.

PMID:
9588654
19.

Qt dispersion and mortality in the elderly.

Perkiömäki JS, Sourander LB, Levomäki L, Räihä IJ, Puukka P, Huikuri HV.

Ann Noninvasive Electrocardiol. 2001 Jul;6(3):183-92.

PMID:
11466135
20.

Prevalence of left ventricular hypertrophy as assessed by electrocardiogram in treated hypertensive persons in general practice.

van den Hoogen JP, van Kruijsdijk MC, van Ree JW, Mokkink HG, Thien T, van Weel C.

J Hum Hypertens. 1993 Oct;7(5):473-7.

PMID:
8263888

Supplemental Content

Support Center